Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Alzheimer’s Solution Shows Promise after Big Pharma’s Cure Fails

Stockhouse Editorial
0 Comments| March 28, 2019

{{labelSign}}  Favorites
{{errorMessage}}

Click to enlargeTwo major pharmaceutical companies developing advanced-stage R&D on Alzheimer’s disease have just pulled the plug ontheir research. The reason why their approach to Alzheimer’s, Aducanumab, failed is because it didn’t account for a factor that is central to R&D conducted by biotechnology Company ProMIS Neurosciences Inc. (TSX:PMN, OTCQB:ARFXF, Forum).

Preclinical studies show the Company's lead antibody candidate, PMN310, demonstrates a high degree of binding to toxic oligomers from Alzheimer's disease brains without binding to plaque or other non-toxic forms of amyloid beta (Aß). Not only has an important competitor dropped out of the race to find an Alzheimer’s treatment, the reason for failure suggests that ProMis is on the right track with its own research.

Click to enlarge

(Image via ProMIS Neurosceinces.)

Stockhouse is joined by Company President and CEO, Dr. Elliot Goldstein to learn more about ProMIS’ research and potential to combat Alzheimer’s Disease.


Listen on Apple PodcastsListen on Google Podcasts


FULL DISCLOSURE: This is a paid article produced by Stockhouse Publishing.



{{labelSign}}  Favorites
{{errorMessage}}

Comments

No comments yet. Be first to comment!

Leave a Comment

You must be logged in to be able to post a comment.

Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today